Short answer
Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Rolling FDA NDA submission initiated for ALXN1840 (tiomolibdate choline) in Wilson disease.
Monopar Therapeutics 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Rolling FDA NDA submission initiated for ALXN1840 (tiomolibdate choline) in Wilson disease
- Regulatory milestone potentially accelerates FDA review of Monopar’s lead therapeutic candidate
- Exhibit 99.1 contains the company’s press release and additional submission details
Item EX-99.1 · Exhibit EX-99.1
- Rolling NDA submission initiated for ALXN1840, advancing Monopar’s lead program toward potential U.S. approval in Wilson disease
- FDA filing authorization enables completed sections to undergo review before the application is complete
- Phase 3 met its primary endpoint, with follow-up spanning 645 patient-years across 266 patients
- Rare Pediatric Disease designation creates potential eligibility for a pediatric Priority Review Voucher upon approval
- Key catalysts remain FDA filing acceptance, regulatory approval, and potential PRV award
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monopar Therapeutics 8-K filings
Get the next MNPR 8-K as it lands
Follow MNPR for push alerts, or ask the research agent what this filing means.